HarvoniChronic hepatitis C infection in children aged 3 to 11 years - new granule and 45/200mg tablet formulations
New formulation and licence extension / variation
Development and Regulatory status
Oct 20Low-dose (45mg/200mg) tablets launched in the UK. Pack size 28 film-coated tablets cost £12,993.33 .
Jul 20Low-dose tablets (45mg/200mg) and granule formulations not yet available .
Jul 20Approved in EU .
Apr 20EU positive opinion for a licence change to recommend use to treat chronic hepatitis C infection in children aged 3 to <12 years. The new indication is treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above. The CHMP also recommended the addition of a new 45 mg/200 mg strength for the film-coated tablets and the introduction of a new pharmaceutical form, coated granules, which will be available in two strengths: 33.75 mg/150 mg and 45 mg/200 mg .
A fixed-dose combination product. Sofosbuvir is a second generation uridine nucleoside analogue which inhibits the NS5B protein of HCV. Ledipasvir is a direct-acting macrocyclic antiviral agent & NS5A serine protease inhibitor.
Prevalence of HCV infection in children and adolescents has been reported to vary from 0.05% to 0.36% in the US and Europe 
Chronic hepatitis C infection in children aged 3 to 11 years - new granule and 45/200mg tablet formulations